Adrenocortical Hyperfunction: Clinical Trials

12 trials for Adrenocortical Hyperfunction, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

12 completed. 12 Phase 3, 1 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 312Completed 12
Phase 21Completed 1

Follow Adrenocortical Hyperfunction: new trials by email Literature Review of Adrenocortical Hyperfunction trials Research Report on Adrenocortical Hyperfunction

Trials (filtered) newest first · largest first

All 12 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study of the Efficacy and Safety of Relacorilant in Patients With Cortisol-Secreting Adrenal Adenomas
Relacorilant, Placebo - Hypercortisolism
Phase 3CompletedCorcept Therapeutics1372020-07-272025-09-04
11C-Metomidate PET/CT for Endocrine Hypertension and Characterisation of Adrenal Tumours
11C-Metomidate PET/CT imaging at Clinical Imaging Research Centre - Primary Aldosteronism Due to Aldosterone Producing Adenoma, Primary Aldosteronism
Phase 2 / Phase 3CompletedChangi General Hospital972019-12-302026-10-26
Open-label Treatment in Cushing's Syndrome
Levoketoconazole - Cushing Syndrome, Cushing Disease
Phase 3CompletedCortendo AB512019-01-072025-06-19
A Study of the Efficacy and Safety of Relacorilant in Patients With Endogenous Cushing Syndrome
Relacorilant, Placebo - Cushing Syndrome
Phase 3CompletedCorcept Therapeutics1522018-11-152025-07-16
Adrenal Artery Ablation Treats Primary Aldosteronism
Endovascular chemical Ablation of Adrenal Gland - Primary Aldosteronism, Hypertension
Phase 3CompletedThird Military Medical University662017-10-012019-07-08
A Study to Assess the Safety and Efficacy of Levoketoconazole in the Treatment of Endogenous Cushing's Syndrome.
Levoketoconazole, Placebo - Endogenous Cushing's Syndrome
Phase 3CompletedCortendo AB842017-09-262022-11-08
Effects of Metyrapone in Patients With Endogenous Cushing's Syndrome
metyrapone - Cushing's Syndrome
Phase 3CompletedHRA Pharma502015-04-012020-09-25
Safety and Efficacy of LCI699 for the Treatment of Patients With Cushing's Disease
osilodrostat, LCI699 matching placebo - Cushings Disease
Phase 3CompletedNovartis Pharmaceuticals1372014-10-062021-01-06
Compassionate Use of CORLUX® (Mifepristone) in the Treatment of Signs and Symptoms of Endogenous Cushing's Syndrome
Mifepristone - Cushing's Disease, Cushing's Syndrome
Phase 3CompletedCorcept Therapeutics42010-11-012014-03-18
SPARTACUS: Subtyping Primary Aldosteronism: a Randomized Trial Comparing Adrenal Vein Sampling and Computed Tomography Scan.
Ct-scan or adrenal vein sampling - Hyperaldosteronism
Phase 3CompletedRadboud University Medical Center2002010-07-012015-07-16
An Extension Study of CORLUX in the Treatment of Endogenous Cushing's Syndrome
mifepristone - Cushing's Syndrome
Phase 3CompletedCorcept Therapeutics302009-07-012014-04-02
A Study of the Efficacy and Safety of CORLUX in the Treatment of Endogenous Cushing's Syndrome
mifepristone - Cushing's Syndrome
Phase 3CompletedCorcept Therapeutics502007-12-012013-08-22

Narrower conditions

Cushing Syndrome (8)  ·  ACTH Syndrome, Ectopic (5)  ·  Pituitary ACTH Hypersecretion (5)  ·  Hyperaldosteronism (3)  ·  Hypertension (3)  ·  Pituitary Diseases (3)  ·  Adrenal Cortex Neoplasms (2)  ·  Choristoma (2)  ·  Diabetes Mellitus, Type 2 (2)  ·  Hirsutism (2)  ·  Adrenal Gland Neoplasms (1)  ·  Adrenocortical Adenoma (1)  ·  Neoplasm Metastasis (1)

Broader conditions

Adrenal Gland Diseases (12)  ·  Endocrine System Diseases (12)  ·  Neoplasms (7)  ·  Brain Diseases (5)  ·  Central Nervous System Diseases (5)  ·  Hyperpituitarism (5)  ·  Hypothalamic Diseases (5)  ·  Nervous System Diseases (5)  ·  Paraneoplastic Endocrine Syndromes (5)  ·  Paraneoplastic Syndromes (5)  ·  Endocrine Gland Neoplasms (4)  ·  Neoplasms by Site (4)  ·  Adrenal Cortex Diseases (3)  ·  Adrenal Gland Neoplasms (3)

Interventions

Corlux (3)  ·  Mifepristone (3)  ·  relacorilant (2)  ·  Metyrapone (1)  ·  Osilodrostat (1)

Sponsors

Corcept Therapeutics (5)  ·  Cortendo AB (2)  ·  Changi General Hospital (1)  ·  HRA Pharma (1)  ·  Novartis Pharmaceuticals (1)  ·  Radboud University Medical Center (1)  ·  Third Military Medical University (1)

Countries

United States (8)  ·  Italy (6)  ·  Spain (6)  ·  Bulgaria (5)  ·  Netherlands (5)  ·  Poland (5)  ·  Romania (5)  ·  Germany (4)  ·  Israel (4)  ·  Austria (3)  ·  France (3)  ·  Hungary (3)  ·  Canada (2)  ·  China (2)  ·  Greece (2)

Top investigators

Andreas Moraitis, MD (2)  ·  Coleman Gross (1)  ·  Coleman Gross, M.D. (1)  ·  Coleman Gross, MD (1)  ·  Fredric Cohen, MD (1)  ·  Jacob Deinum, Dr. (1)  ·  Xavier Valencia, MD (1)

Results publications

PMID 25013998, PMID 26507877, PMID 22466348, PMID 23970725, PMID 27325147, PMID 29099925, PMID 32730798, PMID 33074401, PMID 34059026, PMID 35058882, PMID 37680892, PMID 38696122, PMID 39610378, PMID 41052284, PMID 41730814